323 related articles for article (PubMed ID: 27709313)
1. A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer.
Park KH; Lee S; Park JH; Kang SY; Kim HY; Park IH; Park YH; Im YH; Lee HJ; Park S; Lee SI; Jung KH; Kim YS; Seo JH
Support Care Cancer; 2017 Feb; 25(2):505-511. PubMed ID: 27709313
[TBL] [Abstract][Full Text] [Related]
2. A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer.
Park KH; Sohn JH; Lee S; Park JH; Kang SY; Kim HY; Park IH; Park YH; Im YH; Lee HJ; Hong DS; Park S; Shin SH; Kwon HC; Seo JH
Invest New Drugs; 2013 Oct; 31(5):1300-6. PubMed ID: 23677653
[TBL] [Abstract][Full Text] [Related]
3. An open-label, randomized, multicenter dose-finding study of once-per-cycle pegfilgrastim versus daily filgrastim in Chinese breast cancer patients receiving TAC chemotherapy.
Zhang W; Jiang Z; Wang L; Li C; Xia J
Med Oncol; 2015 May; 32(5):147. PubMed ID: 25820754
[TBL] [Abstract][Full Text] [Related]
4. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
Holmes FA; O'Shaughnessy JA; Vukelja S; Jones SE; Shogan J; Savin M; Glaspy J; Moore M; Meza L; Wiznitzer I; Neumann TA; Hill LR; Liang BC
J Clin Oncol; 2002 Feb; 20(3):727-31. PubMed ID: 11821454
[TBL] [Abstract][Full Text] [Related]
5. A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09.
Lee KH; Kim JY; Lee MH; Han HS; Lim JH; Park KU; Park IH; Cho EK; Yoon SY; Kim JH; Choi IS; Park JH; Choi YJ; Kim HJ; Jung KH; Kim SY; Oh DY; Im SA
Support Care Cancer; 2016 Apr; 24(4):1709-17. PubMed ID: 26423618
[TBL] [Abstract][Full Text] [Related]
6. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer.
Holmes FA; Jones SE; O'Shaughnessy J; Vukelja S; George T; Savin M; Richards D; Glaspy J; Meza L; Cohen G; Dhami M; Budman DR; Hackett J; Brassard M; Yang BB; Liang BC
Ann Oncol; 2002 Jun; 13(6):903-9. PubMed ID: 12123336
[TBL] [Abstract][Full Text] [Related]
7. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
Green MD; Koelbl H; Baselga J; Galid A; Guillem V; Gascon P; Siena S; Lalisang RI; Samonigg H; Clemens MR; Zani V; Liang BC; Renwick J; Piccart MJ;
Ann Oncol; 2003 Jan; 14(1):29-35. PubMed ID: 12488289
[TBL] [Abstract][Full Text] [Related]
8. Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens: a multicenter, randomized, crossover phase 3 study.
Shi YK; Chen Q; Zhu YZ; He XH; Wang HQ; Jiang ZF; Chang JH; Liu YP; Wang AL; Luo DY; Zhang Y; Ke XY; Li WL; Zhang WJ; Wang XW; Zhang YP; Wang JM; Liu XQ
Anticancer Drugs; 2013 Jul; 24(6):641-7. PubMed ID: 23571496
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy.
Kahan Z; Grecea D; Smakal M; Tjulandin S; Bondarenko I; Perjesi L; Illes A; Horvat-Karajz K; Aradi I
BMC Cancer; 2019 Feb; 19(1):122. PubMed ID: 30727980
[TBL] [Abstract][Full Text] [Related]
10. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
Brito M; Esteves S; André R; Isidoro M; Moreira A
Support Care Cancer; 2016 Feb; 24(2):597-603. PubMed ID: 26111956
[TBL] [Abstract][Full Text] [Related]
11. A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel.
Gladkov O; Moiseyenko V; Bondarenko IN; Shparyk Y; Barash S; Adar L; Avisar N
Oncologist; 2016 Jan; 21(1):7-15. PubMed ID: 26668251
[TBL] [Abstract][Full Text] [Related]
12. Factors Associated with Absolute Neutrophil Count Dynamics and Docetaxel-Adryamicin-Cyclophosphamide (TAC) Chemotherapy Induced Neutropenia During Extended Filgrastim Administration in Breast Cancer Patients.
Ashariati A; Bintoro UY; Savitri M; Diansyah MN; Amrita PNA; Romadhon PZ; Wijaya AY; Hendrata WM; Looi SS; Mahmudin AA
Acta Med Indones; 2022 Jul; 54(3):371-378. PubMed ID: 36156473
[TBL] [Abstract][Full Text] [Related]
13. Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies.
Bondarenko IM; Bias P; Buchner A
Support Care Cancer; 2016 Jan; 24(1):267-273. PubMed ID: 26024743
[TBL] [Abstract][Full Text] [Related]
14. Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study.
von Minckwitz G; Kümmel S; du Bois A; Eiermann W; Eidtmann H; Gerber B; Hilfrich J; Huober J; Costa SD; Jackisch C; Grasshoff ST; Vescia S; Skacel T; Loibl S; Mehta KM; Kaufmann M;
Ann Oncol; 2008 Feb; 19(2):292-8. PubMed ID: 17846019
[TBL] [Abstract][Full Text] [Related]
15. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
Nabholtz JM; Cantin J; Chang J; Guevin R; Patel R; Tkaczuk K; Vodvarka P; Lindsay MA; Reese D; Riva A; Mackey J
Clin Breast Cancer; 2002 Oct; 3(4):268-75. PubMed ID: 12425755
[TBL] [Abstract][Full Text] [Related]
16. Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy.
Kosaka Y; Rai Y; Masuda N; Takano T; Saeki T; Nakamura S; Shimazaki R; Ito Y; Tokuda Y; Tamura K
Support Care Cancer; 2015 Apr; 23(4):1137-43. PubMed ID: 25576433
[TBL] [Abstract][Full Text] [Related]
17. Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer.
Kubista E; Glaspy J; Holmes FA; Green MD; Hackett J; Neumann T;
Clin Breast Cancer; 2003 Feb; 3(6):391-8. PubMed ID: 12636878
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study.
Gladkov OA; Buchner A; Bias P; Müller U; Elsässer R
Support Care Cancer; 2016 Jan; 24(1):395-400. PubMed ID: 26092233
[TBL] [Abstract][Full Text] [Related]
19. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma.
Grigg A; Solal-Celigny P; Hoskin P; Taylor K; McMillan A; Forstpointner R; Bacon P; Renwick J; Hiddemann W;
Leuk Lymphoma; 2003 Sep; 44(9):1503-8. PubMed ID: 14565651
[TBL] [Abstract][Full Text] [Related]
20. Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer.
Huang W; Liu J; Zeng Y; Wu F; Li N; Chen K; Hong Y; Wang L; Zhen H; Lin L
Cancer Chemother Pharmacol; 2018 Oct; 82(4):607-613. PubMed ID: 30043207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
